The role of SARS-CoV-2 target ACE2 in cardiovascular diseases.

Szczegóły
Abstrakt

Tytuł:: The role of SARS-CoV-2 target ACE2 in cardiovascular diseases.
Autorzy:: Zhu H; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Zhang L; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Ma Y; Department of Dermatology and Venereology, Peking University First Hospita, Beijing, China.
Zhai M; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Xia L; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Liu J; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Yu S; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Duan W; Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, Xi'an, China.
Źródło:: Journal of cellular and molecular medicine [J Cell Mol Med] 2021 Feb; Vol. 25 (3), pp. 1342-1349. Date of Electronic Publication: 2021 Jan 14.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
MeSH Terms:: Angiotensin-Converting Enzyme 2/*metabolism
COVID-19/*complications
Cardiovascular Diseases/*metabolism
Angiotensin-Converting Enzyme 2/pharmacology ; Animals ; Arrhythmias, Cardiac/metabolism ; Arrhythmias, Cardiac/physiopathology ; COVID-19/metabolism ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/physiopathology ; Diminazene/pharmacology ; Heart Failure/etiology ; Humans ; Hypertension/metabolism ; Hypertension/physiopathology ; Myocardial Infarction/drug therapy ; Myocardial Infarction/metabolism ; Myocardial Infarction/physiopathology ; Recombinant Proteins/pharmacology ; COVID-19 Drug Treatment
References:: Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Hypertension. 2020 Jun;75(6):1382-1385. (PMID: 32208987)
J Biol Chem. 2000 Oct 27;275(43):33238-43. (PMID: 10924499)
J Clin Invest. 2006 Aug;116(8):2218-25. (PMID: 16878172)
JAMA Cardiol. 2020 Jul 1;5(7):819-824. (PMID: 32219357)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Biochem Pharmacol. 2018 May;151:126-134. (PMID: 29428223)
Ther Adv Cardiovasc Dis. 2011 Jun;5(3):159-67. (PMID: 21558085)
Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4. (PMID: 15671045)
Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145)
Circ Res. 2005 Oct 28;97(9):946-53. (PMID: 16179584)
Am J Respir Crit Care Med. 2013 Mar 15;187(6):648-57. (PMID: 23370913)
Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391. (PMID: 32169400)
Mol Med Rep. 2017 Oct;16(4):4791-4796. (PMID: 28791381)
J Am Coll Cardiol. 2008 Aug 26;52(9):750-4. (PMID: 18718423)
Cell Metab. 2018 Jun 05;27(6):1323-1337.e5. (PMID: 29706566)
Cardiovasc Res. 2011 Jul 1;91(1):151-61. (PMID: 21285291)
Eur J Clin Invest. 2018 Jan;48(1):. (PMID: 29130489)
FEBS Lett. 2002 Dec 4;532(1-2):107-10. (PMID: 12459472)
Eur J Pain. 2014 Nov;18(10):1471-9. (PMID: 24733750)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
Exp Physiol. 2010 May;95(5):601-6. (PMID: 19923158)
Hypertension. 2008 Nov;52(5):967-73. (PMID: 18809792)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
Am J Respir Crit Care Med. 2009 Jun 1;179(11):1048-54. (PMID: 19246717)
JAMA Cardiol. 2020 Jul 1;5(7):811-818. (PMID: 32219356)
Europace. 2017 Aug 01;19(8):1280-1287. (PMID: 27738071)
J Mol Cell Cardiol. 2016 Aug;97:180-90. (PMID: 27210827)
J Am Coll Cardiol. 2017 Feb 21;69(7):805-819. (PMID: 28209222)
Hypertension. 2008 Mar;51(3):712-8. (PMID: 18250366)
Rev Peru Med Exp Salud Publica. 2011 Jun;28(2):264-72. (PMID: 21845306)
Heart Vessels. 2017 May;32(5):618-627. (PMID: 28013371)
J Cardiovasc Pharmacol. 2016 Jun;67(6):503-9. (PMID: 26886190)
Eur J Heart Fail. 2020 Jun;22(6):957-966. (PMID: 32412156)
Eur Heart J. 2020 May 14;41(19):1810-1817. (PMID: 32388565)
Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R373-81. (PMID: 16946085)
Hypertension. 2012 Jun;59(6):1195-203. (PMID: 22508831)
J Card Fail. 2010 Feb;16(2):157-63. (PMID: 20142028)
Heart Fail Rev. 2012 Sep;17(4-5):683-91. (PMID: 21638102)
Nature. 2002 Jun 20;417(6891):822-8. (PMID: 12075344)
J Biol Chem. 2002 Apr 26;277(17):14838-43. (PMID: 11815627)
Life Sci. 2017 Jan 15;169:69-75. (PMID: 27633839)
N Engl J Med. 2020 Jun 18;382(25):e102. (PMID: 32356626)
Cardiovasc Res. 2007 Jul 1;75(1):29-39. (PMID: 17499227)
Circ Heart Fail. 2009 Sep;2(5):446-55. (PMID: 19808375)
Pharmacol Rep. 2019 Oct;71(5):958-967. (PMID: 31470292)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63. (PMID: 12829792)
Circulation. 2019 Mar 5;139(10):e56-e528. (PMID: 30700139)
J Pathol. 2004 Jun;203(2):631-7. (PMID: 15141377)
Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1007-19. (PMID: 25724492)
Sci Rep. 2015 Mar 05;5:8794. (PMID: 25740572)
Circ Heart Fail. 2014 Mar 1;7(2):327-39. (PMID: 24389129)
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):107-111. (PMID: 32077660)
Basic Res Cardiol. 2015 May;110(3):21. (PMID: 25804308)
Circ Res. 2000 Sep 1;87(5):E1-9. (PMID: 10969042)
Clin Sci (Lond). 2007 Oct;113(8):357-64. (PMID: 17600530)
Eur Heart J. 2020 May 14;41(19):1818-1820. (PMID: 32388547)
BMJ. 2020 Mar 26;368:m1091. (PMID: 32217556)
Circ Res. 2017 Jun 23;121(1):43-55. (PMID: 28512108)
J Hepatol. 2021 Jan;74(1):168-184. (PMID: 33038433)
Europace. 2014 Nov;16(11):1689-96. (PMID: 24741027)
J Mol Cell Cardiol. 2003 Sep;35(9):1043-53. (PMID: 12967627)
Basic Res Cardiol. 2015;110(4):45. (PMID: 26143546)
Biochem Pharmacol. 2017 Nov 15;144:90-99. (PMID: 28789938)
Eur Heart J. 2020 May 14;41(19):1821-1829. (PMID: 32383763)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Am J Respir Crit Care Med. 2018 Aug 15;198(4):509-520. (PMID: 29570986)
Prog Cardiovasc Dis. 2020 Jul - Aug;63(4):518-524. (PMID: 32305557)
Can J Cardiol. 2017 Jul;33(7):943-946. (PMID: 28279521)
Biochem Pharmacol. 2015 May 1;95(1):38-45. (PMID: 25801006)
Eur Heart J. 2018 Sep 1;39(33):3021-3104. (PMID: 30165516)
J Nephrol. 2010 Jul-Aug;23(4):472-7. (PMID: 20349406)
Am J Physiol Renal Physiol. 2007 Jan;292(1):F82-91. (PMID: 16896185)
Circ Res. 2010 Dec 10;107(12):1470-82. (PMID: 20947830)
J Cell Mol Med. 2021 Feb;25(3):1342-1349. (PMID: 33443816)
Exp Ther Med. 2014 Jun;7(6):1721-1727. (PMID: 24926374)
Int J Mol Sci. 2019 Jun 11;20(11):. (PMID: 31212580)
J Mol Cell Cardiol. 2020 Jul;144:63-65. (PMID: 32422320)
Hypertension. 2006 Oct;48(4):572-8. (PMID: 16908757)
Eur Heart J. 2020 Mar 21;41(12):1298-1306. (PMID: 32118263)
Hum Gene Ther. 2010 Nov;21(11):1545-54. (PMID: 20507236)
PLoS One. 2013 Apr 22;8(4):e61695. (PMID: 23630610)
Nat Commun. 2020 Feb 26;11(1):1058. (PMID: 32103002)
Circ Res. 2010 Feb 5;106(2):373-82. (PMID: 19926873)
Mol Med Rep. 2017 Aug;16(2):1973-1981. (PMID: 28656296)
Circ Res. 2013 Oct 12;113(9):1087-1096. (PMID: 24014829)
Int J Mol Sci. 2020 Jun 12;21(12):. (PMID: 32545595)
Circ Res. 2014 Jul 18;115(3):388-99. (PMID: 24903104)
J Am Coll Cardiol. 2012 Feb 21;59(8):739-47. (PMID: 22340266)
Radiology. 2020 Jun;295(3):715-721. (PMID: 32053470)
Nature. 2020 Sep;585(7824):273-276. (PMID: 32516797)
Exp Physiol. 2016 Dec 1;101(12):1506-1516. (PMID: 27730696)
Grant Information:: 2016YFC1301900 National Key Research and Development Program of China; 81570230 National Natural Science Foundation of China; 81870218 National Natural Science Foundation of China
Contributed Indexing:: Keywords: ACE2; RAS; SARS-CoV-2; cardiovascular diseases
Substance Nomenclature:: 0 (Recombinant Proteins)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
Y5G36EEA5Z (Diminazene)
Entry Date(s):: Date Created: 20210114 Date Completed: 20210219 Latest Revision: 20240330
Update Code:: 20240330
PubMed Central ID:: PMC7875924
DOI:: 10.1111/jcmm.16239
PMID:: 33443816
: Czasopismo naukowe

Full Text Finder

SARS-CoV-2, the virus responsible for the global coronavirus disease (COVID-19) pandemic, attacks multiple organs of the human body by binding to angiotensin-converting enzyme 2 (ACE2) to enter cells. More than 20 million people have already been infected by the virus. ACE2 is not only a functional receptor of COVID-19 but also an important endogenous antagonist of the renin-angiotensin system (RAS). A large number of studies have shown that ACE2 can reverse myocardial injury in various cardiovascular diseases (CVDs) as well as is exert anti-inflammatory, antioxidant, anti-apoptotic and anticardiomyocyte fibrosis effects by regulating transforming growth factor beta, mitogen-activated protein kinases, calcium ions in cells and other major pathways. The ACE2/angiotensin-(1-7)/Mas receptor axis plays a decisive role in the cardiovascular system to combat the negative effects of the ACE/angiotensin II/angiotensin II type 1 receptor axis. However, the underlying mechanism of ACE2 in cardiac protection remains unclear. Some approaches for enhancing ACE2 expression in CVDs have been suggested, which may provide targets for the development of novel clinical therapies. In this review, we aimed to identify and summarize the role of ACE2 in CVDs.
(© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)

Informacja